Literature DB >> 8998402

Neuropeptides and Alzheimer's disease.

C G Gottfries1, S O Frederiksen, M Heilig.   

Abstract

Numerous neuropeptides have been isolated from the human brain and postulated as neurotransmitter candidates. Their biochemical characteristics and anatomical distribution have been elucidated in some detail, but their possible physiological and pathophysiological roles, as well as their utility as diagnostic markers in brain disorders, have been more difficult to establish. The concentrations of several neuropeptides have been measured in postmortem human brain studies and in cerebrospinal fluid (CSF) of patients with Alzheimer's disease. Here we critically review these findings with focus on: (1) the relation between brain tissue and CSF neuropeptide alterations; (2) the specificity of neuropeptide alterations in Alzheimer's disease in relation to other degenerative brain diseases; (3) possible functional implications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8998402     DOI: 10.1016/0924-977x(95)00038-q

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  3 in total

1.  Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.

Authors:  H Kessler; F-G Pajonk; P Meisser; T Schneider-Axmann; K-H Hoffmann; T Supprian; W Herrmann; R Obeid; G Multhaup; P Falkai; T A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

2.  Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.

Authors:  P Morain; J L Robin; G De Nanteuil; R Jochemsen; V Heidet; D Guez
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

3.  Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint.

Authors:  J E Mintzer; D F Mirski; K S Hoernig
Journal:  Dialogues Clin Neurosci       Date:  2000-06       Impact factor: 5.986

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.